Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke

Abstract In stroke patients, loss of skeletal muscle mass leads to prolonged weakness and less efficient rehabilitation. We previously showed that expression of myostatin, a master negative regulator of skeletal muscle mass, was strongly increased in skeletal muscle in a mouse model of stroke. We th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marine Maud Desgeorges, Xavier Devillard, Jérome Toutain, Josiane Castells, Didier Divoux, David Frédéric Arnould, Christopher Haqq, Myriam Bernaudin, Anne-Cécile Durieux, Omar Touzani, Damien Gilles Freyssenet
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ad0c911773f74bc491f220592714b3a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ad0c911773f74bc491f220592714b3a1
record_format	dspace
spelling	oai:doaj.org-article:ad0c911773f74bc491f220592714b3a12021-12-02T11:41:10ZPharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke10.1038/s41598-017-13912-02045-2322https://doaj.org/article/ad0c911773f74bc491f220592714b3a12017-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-13912-0https://doaj.org/toc/2045-2322Abstract In stroke patients, loss of skeletal muscle mass leads to prolonged weakness and less efficient rehabilitation. We previously showed that expression of myostatin, a master negative regulator of skeletal muscle mass, was strongly increased in skeletal muscle in a mouse model of stroke. We therefore tested the hypothesis that myostatin inhibition would improve recovery of skeletal muscle mass and function after cerebral ischemia. Cerebral ischemia (45 minutes) was induced by intraluminal right middle cerebral artery occlusion (MCAO). Swiss male mice were randomly assigned to Sham-operated mice (n = 10), MCAO mice receiving the vehicle (n = 15) and MCAO mice receiving an anti-myostatin PINTA745 (n = 12; subcutaneous injection of 7.5 mg.kg−1 PINTA745 immediately after surgery, 3, 7 and 10 days after MCAO). PINTA745 reduced body weight loss and improved body weight recovery after cerebral ischemia, as well as muscle strength and motor function. PINTA745 also increased muscle weight recovery 15 days after cerebral ischemia. Mechanistically, the better recovery of skeletal muscle mass in PINTA745-MCAO mice involved an increased expression of genes encoding myofibrillar proteins. Therefore, an anti-myostatin strategy can improve skeletal muscle recovery after cerebral ischemia and may thus represent an interesting strategy to combat skeletal muscle loss and weakness in stroke patients.Marine Maud DesgeorgesXavier DevillardJérome ToutainJosiane CastellsDidier DivouxDavid Frédéric ArnouldChristopher HaqqMyriam BernaudinAnne-Cécile DurieuxOmar TouzaniDamien Gilles FreyssenetNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Marine Maud Desgeorges Xavier Devillard Jérome Toutain Josiane Castells Didier Divoux David Frédéric Arnould Christopher Haqq Myriam Bernaudin Anne-Cécile Durieux Omar Touzani Damien Gilles Freyssenet Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke
description	Abstract In stroke patients, loss of skeletal muscle mass leads to prolonged weakness and less efficient rehabilitation. We previously showed that expression of myostatin, a master negative regulator of skeletal muscle mass, was strongly increased in skeletal muscle in a mouse model of stroke. We therefore tested the hypothesis that myostatin inhibition would improve recovery of skeletal muscle mass and function after cerebral ischemia. Cerebral ischemia (45 minutes) was induced by intraluminal right middle cerebral artery occlusion (MCAO). Swiss male mice were randomly assigned to Sham-operated mice (n = 10), MCAO mice receiving the vehicle (n = 15) and MCAO mice receiving an anti-myostatin PINTA745 (n = 12; subcutaneous injection of 7.5 mg.kg−1 PINTA745 immediately after surgery, 3, 7 and 10 days after MCAO). PINTA745 reduced body weight loss and improved body weight recovery after cerebral ischemia, as well as muscle strength and motor function. PINTA745 also increased muscle weight recovery 15 days after cerebral ischemia. Mechanistically, the better recovery of skeletal muscle mass in PINTA745-MCAO mice involved an increased expression of genes encoding myofibrillar proteins. Therefore, an anti-myostatin strategy can improve skeletal muscle recovery after cerebral ischemia and may thus represent an interesting strategy to combat skeletal muscle loss and weakness in stroke patients.
format	article
author	Marine Maud Desgeorges Xavier Devillard Jérome Toutain Josiane Castells Didier Divoux David Frédéric Arnould Christopher Haqq Myriam Bernaudin Anne-Cécile Durieux Omar Touzani Damien Gilles Freyssenet
author_facet	Marine Maud Desgeorges Xavier Devillard Jérome Toutain Josiane Castells Didier Divoux David Frédéric Arnould Christopher Haqq Myriam Bernaudin Anne-Cécile Durieux Omar Touzani Damien Gilles Freyssenet
author_sort	Marine Maud Desgeorges
title	Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke
title_short	Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke
title_full	Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke
title_fullStr	Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke
title_full_unstemmed	Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke
title_sort	pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/ad0c911773f74bc491f220592714b3a1
work_keys_str_mv	AT marinemauddesgeorges pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT xavierdevillard pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT jerometoutain pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT josianecastells pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT didierdivoux pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT davidfredericarnould pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT christopherhaqq pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT myriambernaudin pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT annececiledurieux pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT omartouzani pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke AT damiengillesfreyssenet pharmacologicalinhibitionofmyostatinimprovesskeletalmusclemassandfunctioninamousemodelofstroke
_version_	1718395478921445376

Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke

Ejemplares similares